methods for assessing a patient's risk of developing an adverse drug reaction, for developing therapy for a drug-induced adverse reaction, for assessing a patient's risk for developing sjs, ten or hss, and for identifying a drug that induces sjs , ten or hss

摘要

"METHODS TO ASSESS A PATIENT'S RISK TO DEVELOP AN ADVERSE DRUG REACTION, TO DEVELOP A DRUG-INDUCED ADVERSE REACTION TO ASSESS A PATIENT'S RISK TO DEVELOP SJS, INTEN AND HEND SJS, TEN OR HSS ". The present invention provides a method of predicting a patient's risk of developing adverse drug reactions, particularly Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) or drug hypersensitivity syndrome (HSS). An HLA-13, HLA-B * 1502 allele associated with SJS / TEN has been found to be induced by a variety of drugs. The correlation with HLA-B * 1502 is very significant for carbamazepine-induced SJS / TEN, where all patients tested have the HLA-13 * 1502 allele. In addition, another HLA13 allele, HLA-B * 5801, is particularly associated with allopurinol-induced SJS / TEN or HSS. Milder skin reactions, such as maculopapular eruption, erythema multiforme (MS), urticaria, and fixed drug eruption, are particularly associated with a third allele, HLA-13 * 4601. For either allele, genetic markers (eg, HLA markers, microsatellite, or single nucleotide polymorphism markers) located between the DRB1 and HLA-A region of the specific HLA-B haplotype can also be used for the test.